KEY TAKEAWAYS
- Congenital hyperinsulinism is the leading cause of persistent, severe neonatal hypoglycemia — and it's dangerous because the hypoglycemia is hypoketotic (insulin suppresses ketones), removing the brain's alternative fuel and driving irreversible brain injury.
- Diagnose from a "critical sample" during hypoglycemia: detectable/inappropriate insulin, suppressed ketones (β-hydroxybutyrate) and free fatty acids, a glycemic response to glucagon, and a high glucose infusion requirement (often >8 mg/kg/min).
- Treat the hypoglycemia aggressively and immediately — IV dextrose (high GIR, often central) and glucagon — to protect the brain, then establish maintenance therapy.
- Diazoxide is first-line; the response defines the pathway — diazoxide-unresponsive disease suggests a K_ATP-channel defect (ABCC8/KCNJ11) and prompts genetics + ¹⁸F-DOPA PET.
- Focal vs diffuse matters enormously: focal disease is curable by removing the lesion (partial pancreatectomy); diffuse disease may need near-total pancreatectomy (with a high risk of later diabetes).
- Manage at a specialized multidisciplinary center (endocrinology, ¹⁸F-DOPA PET, pancreatic surgery, pathology).
1. Clinical Overview
Clinical Overview
Congenital hyperinsulinism is a disorder of dysregulated insulin secretion that produces profound, persistent hypoglycemia in the newborn — and it is arguably the most brain-threatening of the neonatal hypoglycemias, because the same hormone that lowers glucose also shuts off the ketone and fatty-acid fuels the brain would otherwise use, so neuroglycopenic injury occurs readily. Many affected infants are macrosomic at birth (fetal hyperinsulinism, like an infant of a diabetic mother) and present with seizures from severe hypoglycemia requiring strikingly high glucose infusion rates. Modern care hinges on two decisions: medical control (with diazoxide first-line and the response guiding further workup), and — for medically refractory disease — distinguishing focal from diffuse disease (via genetics and ¹⁸F-DOPA PET), because focal disease can be surgically cured while diffuse disease requires a very different, more drastic operation.
2. Definitions
| Term | Meaning |
|---|
| Congenital hyperinsulinism (CHI) | Dysregulated insulin secretion → persistent hypoketotic hypoglycemia. |
| Hypoketotic hypoglycemia | Low glucose with inappropriately low ketones — a hallmark of hyperinsulinism. |
| K_ATP channel | β-cell ATP-sensitive potassium channel (ABCC8/SUR1, KCNJ11/Kir6.2) — the commonest genetic target. |
| Focal CHI | A single localized lesion — curable by partial pancreatectomy. |
| Diffuse CHI | All β-cells abnormal — may need near-total pancreatectomy. |
3. Pathophysiology & Genetics
Pathophysiology & Genetics
- Dysregulated insulin secretion → hypoglycemia plus suppression of ketogenesis and lipolysis → the brain loses both glucose and its backup fuels → high risk of injury.
- Genetics: the most severe, often diazoxide-unresponsive cases arise from recessive mutations in the β-cell K_ATP channel genes — ABCC8 (SUR1) and, less commonly, KCNJ11 (Kir6.2). Other genes (GLUD1 — hyperinsulinism-hyperammonemia; GCK; HADH) and syndromes (Beckwith-Wiedemann) also cause CHI.
- Focal disease results from a paternally-inherited K_ATP mutation + paternal isodisomy of 11p15 localized to the lesion — which is why it can be surgically cured.
4. Clinical Presentation
Clinical Presentation
- Persistent hypoglycemia in both fasting and post-prandial states.
- Macrosomia at birth (fetal hyperinsulinism).
- Seizures (~half), jitteriness, lethargy, apnea, poor feeding from severe hypoglycemia.
- Very high glucose infusion rate (GIR) requirement — often >8 mg/kg/min (sometimes much higher) to maintain euglycemia.
5. Diagnostic Approach
Diagnostic Approach
The "critical sample" (drawn during hypoglycemia)
Hyperinsulinism is confirmed by a characteristic pattern when glucose is low:
- Detectable/inappropriately elevated insulin (insulin should be suppressed during hypoglycemia).
- Suppressed ketones (β-hydroxybutyrate) and low free fatty acids (hypoketotic).
- A glycemic response to glucagon (glucose rises — reflecting hyperinsulinism-driven glycogen retention).
- Low IGFBP-1 (suppressed by insulin).
- A high GIR requirement (>8 mg/kg/min) supports the diagnosis.
Determining the form (focal vs diffuse)
- Rapid genetic testing (ABCC8/KCNJ11) — a paternally-inherited recessive mutation suggests focal disease; biallelic/dominant suggests diffuse.
- ¹⁸F-DOPA PET/CT — localizes focal lesions and distinguishes focal from diffuse (high accuracy) — guiding whether partial (focal) or near-total (diffuse) pancreatectomy is appropriate.
- Manage at a specialized center (endocrinology, PET, pathology with frozen-section expertise, pancreatic surgery).
6. Management
Management
Acute (protect the brain)
- Maintain euglycemia aggressively: IV dextrose at a high GIR (often needing a central line for high glucose concentrations); glucagon (bolus/infusion) to correct/prevent hypoglycemia.
- Continuous glucose monitoring/frequent checks; treat every hypoglycemic episode promptly — neuroglycopenia causes irreversible injury.
Maintenance medical therapy
- Diazoxide — first-line (opens the K_ATP channel → suppresses insulin). The response is pivotal:
- Diazoxide-responsive → continue (with attention to side effects — fluid retention [often paired with a diuretic], hypertrichosis; monitor for pulmonary hypertension).
- Diazoxide-unresponsive → suggests a K_ATP defect → proceed to genetics + ¹⁸F-DOPA PET and consider surgery.
- Octreotide (somatostatin analog; long-acting formulations exist) — second-line.
- Nifedipine — limited evidence.
- Frequent, glucose-enriched (± continuous) feeding; glucagon infusion in some.
Surgical therapy (medically refractory)
- Focal disease → focal/partial pancreatectomy (lesionectomy) — potentially curative.
- Diffuse disease → near-total (~98%) pancreatectomy — reduces hypoglycemia but carries a high risk of later diabetes and pancreatic insufficiency.
7. Monitoring
Monitoring
- Glucose (continuous/frequent), GIR, and response to therapy.
- Diazoxide side effects (fluid balance, pulmonary hypertension screening).
- Neurodevelopmental follow-up (hypoglycemic brain injury risk).
- Post-pancreatectomy: for diabetes/pancreatic insufficiency (diffuse) or resolution (focal).
8. Complications
Complications
- Neuroglycopenic brain injury (seizures, developmental impairment) — the central threat.
- Diazoxide: fluid overload, pulmonary hypertension, hypertrichosis.
- Near-total pancreatectomy (diffuse): diabetes (very common long-term) and exocrine insufficiency.
- Persistent/recurrent hypoglycemia despite therapy in severe cases.
9. Safety Warnings
Safety Warnings
- ⚠️ Persistent, severe hypoglycemia needing a high GIR is CHI until proven otherwise — and it's brain-threatening.
- ⚠️ Treat every hypoglycemic episode immediately (dextrose ± glucagon) — hypoketotic hypoglycemia injures the brain fast.
- ⚠️ Draw the critical sample DURING hypoglycemia — it's the diagnostic key.
- ⚠️ Diazoxide response guides everything — unresponsiveness → genetics + ¹⁸F-DOPA PET.
- ⚠️ Distinguish focal (curable) from diffuse before surgery — get the PET.
- ⚠️ Refer to a specialized multidisciplinary CHI center.
10. Common Mistakes
Common Mistakes
- Under-treating persistent hypoglycemia (inadequate GIR/glucagon).
- Not obtaining the critical sample during a hypoglycemic episode.
- Failing to escalate workup when diazoxide fails (genetics + PET).
- Operating without distinguishing focal from diffuse (missing a curable focal lesion or doing an unnecessary near-total resection).
- Ignoring diazoxide side effects (fluid overload, pulmonary hypertension).
- Not arranging neurodevelopmental follow-up.
- Confusing transient neonatal hyperinsulinism (IDM/IUGR/stress) with persistent CHI.
11. Clinical Pearls
Clinical Pearls
- 💡 Low sugar + low ketones = hyperinsulinism (hypoketotic hypoglycemia).
- 💡 Big baby + seizures + huge glucose need → think CHI.
- 💡 Catch it during the low — the critical sample is drawn while hypoglycemic.
- 💡 Diazoxide is the litmus test — no response points to a K_ATP defect.
- 💡 Focal is curable; diffuse is drastic — the PET decides the operation.
- 💡 Every low is a brain risk — treat instantly.
12. Summary Table
Summary Table
| Domain | Bottom line |
|---|
| What | Leading cause of persistent, severe neonatal hypoglycemia; hypoketotic |
| Genetics | Most severe from ABCC8/KCNJ11 (K_ATP channel); also GLUD1, syndromes |
| Presentation | Macrosomia, seizures, high GIR (>8 mg/kg/min) |
| Diagnosis | Critical sample: detectable insulin + suppressed ketones/FFA + glucagon response + high GIR |
| Form | Genetics + ¹⁸F-DOPA PET → focal (curable) vs diffuse |
| Acute | High-GIR IV dextrose ± glucagon — protect the brain |
| Maintenance | Diazoxide first-line (response guides workup); octreotide; feeding |
| Surgery | Focal → partial pancreatectomy (cure); diffuse → near-total (diabetes risk) |
13. Step-by-Step Bedside Algorithm
PERSISTENT / SEVERE NEONATAL HYPOGLYCEMIA (high GIR need, ± macrosomia/seizures)
│
▼
ACUTE: maintain euglycemia AGGRESSIVELY — high-GIR IV dextrose (± central line) + GLUCAGON
(treat every low immediately — hypoketotic hypoglycemia → brain injury)
│
▼
DRAW CRITICAL SAMPLE DURING HYPOGLYCEMIA:
detectable/inappropriate INSULIN + suppressed KETONES/free fatty acids
+ GLYCEMIC RESPONSE TO GLUCAGON + low IGFBP-1 + high GIR → confirms HYPERINSULINISM
│
▼
START DIAZOXIDE (first-line) → assess RESPONSE
├─ Responsive → continue (watch fluid overload / pulmonary hypertension)
└─ UNRESPONSIVE → RAPID GENETICS (ABCC8/KCNJ11) + ¹⁸F-DOPA PET
→ FOCAL (paternal mutation; localized PET uptake) → PARTIAL PANCREATECTOMY (curative)
→ DIFFUSE (biallelic/dominant) → medical therapy (± octreotide); if refractory →
NEAR-TOTAL PANCREATECTOMY (diabetes/insufficiency risk)
│
▼
Manage at specialized CHI center; neurodevelopmental follow-up
14. References to Verify
Confirm each against the primary source before clinical or published use.
- 1.Consensus: 2023 international consensus on the diagnosis and management of congenital hyperinsulinism (diazoxide first-line; workup). (Verify.)
- 2.Clinical features: de Lonlay-Debeney P, et al. Clinical Features of 52 Neonates with Hyperinsulinism. NEJM. 1999. (Verify.)
- 3.Genetics: ABCC8/KCNJ11 K_ATP-channel mutations; focal disease (paternal mutation + 11p15 isodisomy). (Verify.)
- 4.Imaging: ¹⁸F-DOPA PET/CT for focal vs diffuse localization. (Verify.)
- 5.Surgery/outcomes: partial vs near-total pancreatectomy and post-operative diabetes risk. (Verify.)